title: Treatments of choice for bullous pemphigoid.
abstract: Bullous pemphigoid (BP) is the most frequently occurring autoimmune blistering disease in Europe and North America. Although it is primarily a disease of the elderly, children and young adults can also develop it. The aim of treatment is to suppress the clinical signs and symptoms of BP without over-treating the patient, because BP tends to spontaneously remit in most patients within approximately 5 years. Mild or localized disease may respond to super-potent topical corticosteroids alone or in combination with tetracyclines with or without niacinamide. More severe or generalized disease usually requires systemic treatment with prednisolone (dose range from 20-70 mg/d). Additional immunosuppressant therapy is necessary for more refractory disease.
authors.affiliation: Department of Dermatology, Oxford Radcliffe Hospital, Oxford, UK.
authors.forename: S M
authors.initials: SM
authors.lastname: Cooper
authors.forename: F
authors.initials: F
authors.lastname: Wojnarowska
mesh_terms: D006801:Humans; D010391:Pemphigoid, Bullous / Q000188:drug therapy* / Q000276:immunology